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Backround: Leptin a cytokine protein secreted by adipose tissue raises considerable interest as a potential mediator 
of the protective eﬀ  ects of fat mass on bone tissue. After menopause heavier women conserve bone mass better than 
those with lower body weight. The protective eﬀ  ect of obesity on bone mass has been ascribed to a high body fat con-
tent. As Leptin levels reﬂ  ect the body fat content it has emerged as a possible mediator of these protective eﬀ  ects.
Methods: A search of the available literature focused on the role of leptin on bone tissue.
Results: Both peripheral and central action of leptin on bone metabolism have been proposed. In vitro and in vivo 
evidence supports the hypothesis that leptin can act directly or indirectly on bone remodelling by modulating both 
osteoblast and osteoclast activities. However, studies in humans have not yet been able to conﬁ  rm these actions possibly 
because of the shifting balance between stimulatory direct action and suppressive indirect action of leptin on bones 
via the hypothalamus. The eﬀ  ects of oestrogen decline and deﬁ  ciency during natural or artiﬁ  cially induced menopause 
and administration of hormone replacement therapy has on leptin production remains controversial. Various studies 
have shown diﬀ  erences in leptin values in pre- and postmenopausal women. The existing clinical data on this issue 
are discordant. 
Conclusion: Larger clinical studies are necessary to clarify leptin’s role in vivo and to assess the contribution of the 
central and peripheral role of leptin in the overall maintenance of bone turnover in human beings.
INTRODUCTION
Leptin, a member of the helical cytokine family is the 
soluble 16-kDa product of the OB (Lep) (Ob for obese 
and Lep for leptin) gene on human chromosome 7q31.3 
and chromosome 6 in mouse1. Leptin is mainly produced 
by white fat cells, it is also produced by brown adipose 
tissue, placenta (syncytiotrophoblasts), ovaries, skeletal 
muscle, stomach (lower part of fundic glands), mammary 
epithelial cells, bone marrow, pituitary and liver1. Leptin 
ﬁ  rst emerged as a component of a regulatory loop linking 
fat mass to food intake and energy expenditure but later 
also raised considerable interest as a potential mediator of 
the protective eﬀ  ects of fat mass on bone tissue2. The pro-
tective eﬀ  ect of obesity on bone mass has been ascribed 
to a high body fat content. Leptin is produced by adipose 
cells, with its levels reﬂ  ecting the amount of adipose tis-
sue, so leptin logically emerged as a possible mediator of 
protectice eﬀ  ect of fat tissue on bone. Leptin exerts its 
eﬀ  ects through interaction with six types of receptors. 
Leptin receptors are divided into secretory (ObRe), long 
(ObRb) and short forms (ObRa, ObRc, ObRd, ObRf). 
(ObRe) acts as a binding protein for leptin in the plasma 
in humans and mice and is important for leptin transfer 
into the brain. ObRb is the only receptor isoform that 
contains active intracellular signaling domains. This 
receptor is found in a number of hypothalamic nuclei 
where it exerts its eﬀ  ects. ObRb receptors are also found 
in other cells including osteoblasts. Leptin binds to the 
Ventral Medial nucleus of the hypothalamus, known as 
the “satiety center” where it signals to the brain a sensa-
tion of satiety. Leptin also works by inhibiting the activity 
of neurons that contai the neuropeptide Y (NPY) and 
agouti-related peptide (AgRP), and stimulating neurons 
expressing α-melanocyte-stimulating hormone (α-MSH). 
The NPY neurons are a key element in the regulation of 
appetite. Once leptin has bound to the Ob-Rb receptor, 
it activates the stst 3 molecule, which is then phosphor-
ylated and travels to the nucleus,where it is presumed, to 
eﬀ  ect changes in gene expression. One of the main eﬀ  ects 
on gene expression is the down-regulation of the expres-
sion of the endocannabinoids, responsible inter alia for 
increasing appetite. There are several other intracellular 
pathways activated by leptin, but less is known about how 
they function in this system. 
Mechanism of leptin action on bone 
The exact inﬂ  uence of leptin on bone metabolism 
has not yet been clariﬁ  ed. The literature is inconsistent and 
conﬂ  icting. Leptin is emerging as central in two entirely 
diﬀ  erent bone -controlling mechanisms. The ﬁ  rst is the 
indirect one. It was discovered by Ducy and al.3–8 in mu-
tant mice and rats that either cannot produce or cannot 
respond to, leptin. Leptin secreted from fat cells is car-
ried by the ObRa receptors of vascular endothelial cells 
across the blood-brain-barrier where it activates ObRb re-
ceptors in the hypothalamus. These signals then stimulace 
expression of HOBIF (hypothalamic osteoblast inhibitory 
factor) which when released, lowers the matrix-making 
ability of osteoblasts2–8. These authors discovered what 
they believed to be the reason why obese Ob(Lep)–/– mice, 
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of leptin, and thus estrogen, actually have an abnormally 
high bone mass3–8. They found that intracerebroventricu-
lar injections of leptin actually caused the bone mass to 
decrease. It is assumed that leptin stimulates the brain to 
release HOBIF. Another part of central control mecha-
nism of leptin is the NPY and its Y2 receptor, which may 
stimulate HOBIF release. In mice lacking neuropeptide 
2 (NPY2) receptors in the hypothalamus deletion of hy-
pothalamic NPY2 receptors resulted in increased bone 
mass without any obvious endocrine imbalance that 
would aﬀ  ect bone homoeostasis, which shows that these 
receptors regulate bone formation by alterating autonomic 
function9. A loss of either Y2 receptors or leptin should re-
duce HOBIF and increase osteoblast productivity9. Elefte-
riou et al.10 found that NPY-deﬁ  cient mice have normal 
bone mass, which is in contrast to the mice deﬁ  cient in 
NPY2 receptor. NPY4 receptor deﬁ  cient mice have nor-
mal bone mass, whereas double knockout of NPY2 and 
NPY4 receptors leads to a greater increase in bone vol-
ume than in mice deﬁ  cient only in the NPY2 receptor11. 
Both receptors modulate sympathetic outﬂ  ow in the brain 
stem. Augmented bone formation in the double knockout 
mouse suggests synergistic activity between NPY2 and 
NPY4 receptor pathways11. The second direct mechanism 
of leptin exerts its osteotrophic eﬀ  ects by promoting diﬀ  er-
entiation of bone marrow stromal cells into osteoblasts12 
and by inhibiting osteoclast generation13. Circulating leptin 
penetrates the bone marrow, where it joins the autocrine/
paracrine leptin from early cells of the osteoblast lineage 
and from late-stage, matrix-mineralizing osteoblasts or 
from early osteocytes to stimulate the production of IGF-
1. IGF-1 in turn stimulates the proliferation of osteoblast 
precursors makes the osteoblastic lineage cells more re-
sistant to apoptosis, and further enhances bone formation 
through suppression of osteoclast generation by causing 
osteoblastic stromal cells to make less RANKL (NF-kap-
paB ligand) which stimulates osteoclast generation, and 
by stimulating the production of the osteoclast-suppress-
ing OPG (osteoprotegerine) the osteoclast suppressor. 
Osteoblasts freshly isolated from adult humans have 
functional ObRb receptors14. Bassilana et al.15 have found 
that human mesenchymal stem cells begin expressing 
both the nonfunctional, leptin transvascular-transporting 
ObRa, the fully functional long ObRb signal-transducing 
receptors, and leptin itself during osteoblastic diﬀ  erentia-
tion. Reseland te al.16 have found that human osteoblasts 
start making and secreting leptin when they are either in 
the late, matrix-mineralizing stage or when changing to 
osteocytes. Leptin has also stimulates the proliferation 
of cultured human osteoblasts17, and it has been shown 
to cause human bone marrow stromal cells to express 
alkaline phosphatase, collagen-I, and osteocalcin and to 
mineralize matrix12. 
Although data from cultured human bone cells point to 
leptin as a direct stimulator of bone growth and a suppres-
sor of bone resorption, the correlation between the serum 
leptin level and BMD (bone mineral density) in humans 
is so far equivocal, possibly because of a shifting balance 
between the cytokine's stimulatory direct action and sup-
pressive indirect action on bones via the hypothalamus. 
In human beings, positive, negative, or no associations 
between serum leptin levels and bone mineral density 
have been reported. Pasco et al.18 have reported that serum 
leptin levels are positively correlated to the bone mineral 
content. Results of Blain et al.19 demonstrated that leptin 
is an independent predictor of whole body and femoral 
neck BMD in postmenopausal women. Yamauchi et al.20 
showed that in postmenopausal women plasma leptin lev-
els were positively correlated with BMD values. Moreover, 
plasma leptin levels were signiﬁ  cantly lower in women 
with vertebral fractures than in those without fractures. 
The study of Di Tomaselli et al.21 also conﬁ  rms a signiﬁ  -
cant correlation between serum leptin and BMD in early 
postmenopausal women, but the correlation was lost dur-
ing progression of the postmenopausal period. Thomas 
et al.22 have reported that BMD is positively correlated 
to fat mass and the serum leptin level in women. Z. Nagy 
et al.23 found a negative correlation between serum leptin 
levels and radial and femoral BMD in postmenopausal 
women. On the other hand P. Hadji et al.24 reported that 
bone mass is not correlated with the serum leptin level 
in pre or postmenopausal women. Goulding et al. found 
no signiﬁ  cant correlations between plasma leptin and dy-
namic markers of bone resorption or formation25. Rauch 
et al. also failed to ﬁ  nd a relationship between bone mass 
and serum leptin levels by examining total and trabecu-
lar bone density at the distalradius in adult women and 
reported no correlation, between plasma leptin level and 
bone turnover markers in adult women26. 
Diﬀ  erences in leptin levels between men and women 
Leptin possesses dimorphism, it is higher in women 
than in men. Leptin pulse amplitude is two to three times 
higher in women than in men and the expression rate of 
leptin mRNA in subcutaneous fat tissue is signiﬁ  cantly 
higher in females than in males27. Moreover, in vitro, the 
leptin secretion rate of men’s subcutaneous adipose tis-
sue is 66 % that of women’s28. This would suggest a de-
pendence of leptin on estrogen. Some authors admitt the 
diﬀ  erence may result not from higher estrogen level in 
women, rather from a suppressive eﬀ  ect of high levels of 
circulating androgens in men on leptin production29, 30. It 
has been suggested that androgens reduce the regulation 
of leptin secretion29, 31. Administration of testosterone re-
duces the expression of leptin mRNA in men. However, 
the inﬂ  uence of circulating androgens is not supported 
by other studies33,34. In these studies, leptin levels were 
invertly correlated with androgen levels. 
Leptin and menopause
Postmenopausal women, whose estrogen levels nat-
urally or artiﬁ  cially decline, are at the highest risk for 
developing osteopenia and osteoporosis. The inﬂ  uence 
of hormonal changes during menopause on leptin levels 
is still poorly understood. It is well documented that the 
serum concentration of leptin secreted by adipocytes cor-
relates positively with the amount of fat mass and BMI35–
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women may be the best adiposity-related predictor of se-
rum leptin39. As a consequence of the decline in endog-
enous estrogens and reduced energy during menopause 
women tend to gain body fat40. After menopause heavier 
women conserve bone mass better than those with lower 
body weight. The protective eﬀ  ect of obesity on bone 
mass has been ascribed to a high body fat content. As 
a result of menopause transition the levels of circulating 
estrogens decrease whereas the adrenal glands continue 
to secrete androgen precursors. Inactive steroid precur-
sors are aromatized to estrogens in adipose tissue. The 
relative increase in the androgen/estrogen ratio is likely 
to be important for the fat distribution shift41. Postmeno-
pausal women manifest shift to a abdominal fat distribu-
tion (android type of obesity), which is associated with a 
more androgenic proﬁ  le with increased free testosterone 
levels and lower sex hormone-binding globulin (SHBG) 
levels. The shift to abdominal adiposity shows itself in 
the changes of WHR (waist to hip ratio). The connection 
between serum leptin concentration and WHR is con-
troversial. Some authors have shown that serum leptin 
levels are higher in android obese women than in gynoid 
ones42, but other studies demonstrate a lack of correlation 
between serum leptin concentration and the type of obes-
ity. Martinez-Carpio et al. found no correlation between 
leptin and WHR in postmenopausal women, but they 
found signiﬁ  cant correlations between leptin and weight, 
BMI and chest, waist and hip circumferences43. This is in 
agreement with the results of Tupikowska and Minocci 
et al.34, 44. They also showed that WHR values were not 
correlated with leptin concentrations44. They suggest that 
subcutaneous abdominal fat is a determinant of leptin 
concentration, independently of the amount of fat mass, 
whereas the contribution of preperitoneal visceral fat is 
not signiﬁ  cant. 
Various studies have shown diﬀ  erences in leptin val-
ues in pre- and postmenopausal women. Some authors 
suggest that serum leptin concentration are lower in the 
post-menopausal period. Rosenbaum et al.29 Shimizu et 
al.45 They report that pre-menopausal women have higher 
leptin production than postmenopausal women. However 
there are also reports indicating that decrease in estrogen 
levels in postmenopausal status has no direct eﬀ  ect on 
adipose tissue leptin production or concentrations31,34, 
45–48. There are only few studies comparing the leptin level 
in women with artiﬁ  cially induced menopause before and 
after ovarectomy. When women with previously normal 
cycles before surgery were studied during the fourth post-
operative day period after bilateral ovariectomy a signiﬁ  -
cant reduction in leptin concentrations was found. There 
was a positive correlation of leptin values with estradiol 
and progesterone before and after the operation49.
Several authors have investigated plasma leptin levels 
in postmenopausal women during administration of HRT 
(hormone replacement therapy). Some results show that 
estrogens can regulate leptin production and its serum 
concentration45. Some studies reported no diﬀ  erences in 
serum leptin levels between users and non – users of hor-
monal replacement therapy, while others showed both de-
creased and increased leptin levels. Existing clinical data 
addressing this issue are discordant. Di Carlo et al.50 found 
increased serum leptin level in untreated postmenopausal 
women decreased to premenopausal values after hormo-
nal treatment. These results suggested that sex hormone 
replacement therapy can modulate leptin levels. In obese 
and non-obese postmenopausal women studied before and 
after HRT administration, plasma leptin levels showed an 
increase following treatment which was more pronounced 
in obese women51. Also intranasal and oral HRT had the 
eﬀ  ect of increasing the levels of leptin after 24 weeks in 
healthy postmenopausal women52. Other authors indicate 
that neither endogenous E2 nor sex hormone replacement 
therapy has any eﬀ  ect on serum leptin concentration34. 
These results support the hypothesis that the expression of 
leptin in adipocytes and circulating levels of this hormone 
are not related to the estrogen levels and type of hormonal 
therapy used. Hickey et al. analyzed data on postmeno-
pausal women taking part in a cardiovascular risk factor 
study and found that leptin concentrations were similar in 
sex hormone users and non-users53. Also the results of the 
San Antonio heart study also showed no relation between 
serum leptin levels and menopausal status or postmeno-
pausal sex hormone use54. Gower et al. compared HRT-
treated postmenopausal women with untreated controls. 
There were no signiﬁ  cant determinants of serum leptin 
levels55. In a randomized placebo-controlled study in post-
menopausal women with type 2 diabetes mellitus treated 
with transdermal E2 +NETA (estradiol + norethisteorne 
acetate), no signiﬁ  cant alterations in leptin levels were 
found56. The group of Di Tomaselli evaluated serum leptin 
levels in healthy HRT treated and untreated postmenopau-
sal women. In women taking HRT, serum leptin levels did 
not change signiﬁ  cantly throughout the study period57. 
In an large sample of healthy postmenopausal users and 
non-users of hormone replacement therapy, Hadji et al. 
showed that neither sex hormone supplementation nor 
serum estrogen concentrations had any eﬀ  ect on leptin 
concentration, even after adjustment for BMI24. Other 
investigators take the possibility into account that diﬀ  er-
ences in leptin level may depend on the type and dose of 
HRT used58. Gower et al. measured leptin in women with 
an untreated spontaneous cycle and with a cycle treated 
withdiﬀ  erent types of HRT. Women treated with estradiol 
plus progesterone had elevated serum leptin concentra-
tions, but when estradiol was administered alone, leptin 
concentrations were not aﬀ  ected56. Serum leptin levels 
were increased in postmenopausal women treated with 
short-term HRT independent of changes in fat mass; in 
the same women, progesterone administration alone did 
not inﬂ  uence leptin levels. Some authors suggest that only 
a supraphysiological estrogen concentration can act on 
adipocytes and modulate leptin production. It is possible 
that diﬀ  erent doses of estradiol exert a more pronounced 
eﬀ  ect on circulating leptin59. Also studies in women with 
artiﬁ  cial menopause show similar results. Messinis et al. 
studied leptin levels in ovariectomized normal women 
treated with estradiol plus progesterone60. They found that 
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tin levels59, 61. On the other hand administration of HRT 
to ovariectomized women starting 15 days after surgery 
did not modify leptin levels62.
Leptin administration as a treatment for osteopenia
Leptin might be used to treat osteopenia only if it 
can be engineered to avoid suppressive indirect eﬀ  ects 
on bones via the hypothalamus – avoid the hypothala-
mus and refrain from stimulating HOBIF expression. 
Only a very small group of humans is knowm to possess 
homozygous mutations for the leptin gene. Up to date, 
two United Kingdom families of Pakistani origin carrying 
a frameshift/premature mutation, and one Turkish family 
carrying a missense mutation, have been described21. This 
mutation leads to a constant demand for food, resulting in 
severe obesity. This condition can be successfully treated 
by the administration of recombinant human leptin and 
theroretically administration of leptin could be used to 
treat osteopenia in these subjects. 
CONCLUSION
Although data from cultured human bone cells point 
to leptin as a direct stimulator of bone growth and a sup-
pressor of bone resorption, understanding of leptin’s 
role in human bone-remodelling is not yet deﬁ  ned. The 
exact role of leptin on bone mass remains unclear. The 
correlation between the serum leptin levels and BMD in 
humans is so far equivocal, possibly because of a shift-
ing balance between the cytokine's stimulatory direct 
action and suppressive indirect action on bones via the 
hypothalamus. The eﬀ  ect that oestrogen decrease and deﬁ  -
ciency during menopause and administration of hormone 
replacement therapy has on leptin production and con-
tribution of leptin on emergence of osteopenia remains 
controversial. Existing clinical data addressing this issue 
are discordant. Larger clinical studies are therefore nec-
essary to clarify leptin’s role in vivo and to assess the 
contribution of the central and peripheral role of leptin to 
the overall maintenance of bone turnover in human beings 
and how leptin contributes to the mechanism of loss of 
bone mass during artiﬁ  cial and natural menopause.
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